AI Technology Group Amends Merger Deal with AVM Biotech and Biomed 360, Extends Closing to July 2026

AI Technology Group Inc.

Amendment provides that $1M Tranche 1 convertible at $1.00/share and $1M of Tranche 2 at $2.50/share have been funded.
Remaining three $1M Tranche 2 increments due by Feb 28, Apr 30, and Jun 30, 2026, convertible at $2.50/share.
Tranche 3 of $10M to $25M due at closing, also convertible at $2.50/share with 10% simple interest.
Closing date extended from March 31, 2026 to July 26, 2026 or as mutually agreed in writing.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AI Technology Group Inc. amended Agreement and Plan of Merger with AVM Biotechnology Inc. and Biomed 360 Solutions Corp. valued at Amended investment obligations and extended closing date from March 31, 2026 to July 26, 2026 (effective 2026-01-27).

Action: amendment
Agreement: merger
Counterparty: AVM Biotechnology Inc. and Biomed 360 Solutions Corp.
Value: Amended investment obligations and extended closing date from March 31, 2026 to July 26, 2026
Effective: 2026-01-27

Exact text from the filing

On January 27, 2026, and pursuant to the Agreement and Plan of Merger , the Corporation, AVM and Biomed 360 have amended the terms of the Agreement and Plan of Merger as follows:

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001477932-26-000500

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.